CHILDRENS HOSPITAL MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $115.6M
- Transactions
- 10,012
- Companies
- 40
- Average per transaction
- $11,550
Who reported the payments
| Pfizer | $21,747,706 |
| Regeneron | $11,651,378 |
| AstraZeneca | $6,903,380 |
| Novartis | $4,623,573 |
| E.r. Squibb & Sons, L.L.C. | $4,397,923 |
| Merck | $3,483,535 |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,460,341 |
| PTC Therapeutics, Inc. | $3,002,511 |
| Varian Medical Systems, Inc. | $2,952,318 |
| Sobi, Inc | $2,468,849 |
| Shire North American Group Inc | $2,306,395 |
| Vertex | $2,227,874 |
| AbbVie | $2,084,651 |
| Amgen | $2,065,268 |
| Sanofi US Services Inc. | $1,851,290 |
| Siemens Medical Solutions USA, Inc. | $1,819,043 |
| Sanofi | $1,489,844 |
| Eli Lilly | $1,476,504 |
| Edwards Lifesciences | $1,462,500 |
| Gilead | $1,320,974 |
| Janssen Research & Development, LLC | $1,320,742 |
| Novo Nordisk | $1,303,705 |
| Amicus Therapeutics, Inc. | $1,093,621 |
| Ipsen Biopharmaceuticals, Inc | $994,847 |
| Exeltis, USA Inc. | $963,651 |
| Swedish Orphan Biovitrum AB | $842,302 |
| Ventana Medical Systems, Inc. | $827,143 |
| Acadia Pharmaceuticals Inc | $808,911 |
| Biomarin Pharmaceutical Inc. | $790,966 |
| Sarepta Therapeutics, Inc. | $744,420 |
| Genetix Biotherapeutics Inc | $734,353 |
| Mirum Pharmaceuticals, Inc. | $690,932 |
| Philips North America LLC | $673,437 |
| Emergent Biosolutions Inc. | $624,431 |
| Bristol Myers Squibb | $615,799 |
| Astrazeneca UK Limited | $581,190 |
| Roche Products Limited | $536,054 |
| Incyte Corporation | $529,150 |
| Medtronic | $527,299 |
| F. Hoffmann-la Roche AG | $523,300 |